Brain’s Immune Cells Offer New Hope in Alzheimer’s Fight
Table of Contents
A groundbreaking new study suggests that specialized immune cells within the brain could hold the key too preventing the onset of Alzheimer’s disease, perhaps paving the way for innovative therapies focused on bolstering this natural defense mechanism.
For years, research has indicated a complex relationship between microglia, the brain’s resident immune cells, and Alzheimer’s. While capable of mitigating some symptoms, microglia can also exacerbate the disease through inflammation. Now, an international team of scientists has delved deeper into the mechanisms governing how these cells switch between protective and harmful states.
Using mouse models of Alzheimer’s, researchers at the icahn School of Medicine, led by neuroscientist Pinar Ayata, discovered that microglia transition into a neuroprotective state when they encounter amyloid-beta protein clumps – a hallmark of the disease. “Microglia are not simply destructive responders in Alzheimer’s disease – they can become the brain’s protectors,” explained a neuroscientist from the Icahn School of Medicine in New York. “This finding extends our earlier observations on the remarkable plasticity of microglia states and their crucial roles in diverse brain functions.”
(Image credit: Ayata et al., Nature, 2025)
The Protective Microglia Profile
The research pinpointed two key characteristics that define this beneficial microglia subtype. These cells exhibited lower levels of PU.1, a protein previously linked to Alzheimer’s, and increased expression of CD28, a protein vital to the broader immune system.
Microglia displaying this unique combination proved more effective at slowing the accumulation of amyloid-beta protein clumps in the brains of mice, while also reducing the aggregation of tau – another toxic protein associated with Alzheimer’s. Conversely, when researchers halted CD28 production in mice, they observed a surge in harmful, inflammation-inducing microglia and a corresponding increase in amyloid-beta plaques.
These findings align with previous studies indicating that the onset of Alzheimer’s often occurs later in life among individuals with a genetic predisposition towards lower PU.1 expression in specific cells. “These results provide a mechanistic description for why lower PU.1 levels are linked to reduced Alzheimer’s disease risk,” stated a geneticist from the Icahn School of Medicine.
Harnessing the Brain’s Natural Defenses
While this represents a natural defense against Alzheimer’s,it’s currently insufficient to halt the disease’s progression entirely. Researchers are optimistic about the potential for future therapies to amplify the presence of this protective microglia subtype, but emphasize the need to confirm that microglia function similarly in humans.
Alzheimer’s is a notoriously complex disease, influenced by numerous risk factors. An effective treatment will likely require a multi-pronged approach, and one promising avenue for future research is converting microglia into this neuroprotective mode.
The study also deepens our understanding of Alzheimer’s within the context of the overall immune system. The modified microglia identified in the research exhibit behavior similar to T cells that circulate throughout the rest of the nervous system. “This finding comes at a time when regulatory T cells have achieved major recognition as master regulators of immunity, highlighting a shared logic of immune regulation across cell types,” noted an epigeneticist from the Rockefeller University. “It also paves the way for immunotherapeutic strategies for Alzheimer’s disease.”
The research was published in Nature in July 2025.
